Bruce Ovbiagele1, Patrick D Lyden, Jeffrey L Saver. 1. Stroke Center and Department of Neurology, University of California at Los Angeles, 710 Westwood Plaza, Los Angeles, CA 90095, USA. Ovibes@mednet.ucla.edu
Abstract
BACKGROUND: Three months is the standard timepoint for assessing final functional status after acute ischemic stroke in phase 3 clinical trials. Earlier reliable timepoints for outcome ascertainment would facilitate care quality improvement programs that employ administrative datasets and reduce the loss to follow-up observed in many stroke clinical trials. We assessed whether day 30 global disability status reliably predicts final 3-month disability outcome among acute stroke patients. METHODS: Data of 5,997 subjects in acute stroke trials conducted between 1998 and 2006 from the Virtual International Stroke Trials Archive dataset were partitioned into a derivation cohort (n = 4,051) and a validation cohort (n = 1,946). Global disability was assessed with modified Rankin Scale (mRS). To evaluate the association of day 30 vs day 90 mRS, weighted kappa agreement was computed and then adjusted using multivariable ordinal logistic modeling. RESULTS: Overall, mean age was 67.6 +/- 12.4 years; 2,541 (45.2%) were women. Day 30 mRS score correlated strongly with day 90 (r = 0.87, p < 0.001); weighted kappa agreement was 0.86 (95% confidence interval 0.85-0.87, p < 0.001). In multivariable logistic regression analysis, day 30 mRS was the dominant variable associated with day 90 mRS, accounting for 65.6% of the variance. Nine other baseline variables were associated with outcome, but collectively explained only an additional 1.8% of the variance. CONCLUSIONS: After an index ischemic stroke, global disability status at 1 month reliably estimates final 3-month disability outcomes. One-month disability status alone may be dependable and efficient as an outcome measure in stroke quality improvement programs and select clinical trials.
BACKGROUND: Three months is the standard timepoint for assessing final functional status after acute ischemic stroke in phase 3 clinical trials. Earlier reliable timepoints for outcome ascertainment would facilitate care quality improvement programs that employ administrative datasets and reduce the loss to follow-up observed in many stroke clinical trials. We assessed whether day 30 global disability status reliably predicts final 3-month disability outcome among acute strokepatients. METHODS: Data of 5,997 subjects in acute stroke trials conducted between 1998 and 2006 from the Virtual International Stroke Trials Archive dataset were partitioned into a derivation cohort (n = 4,051) and a validation cohort (n = 1,946). Global disability was assessed with modified Rankin Scale (mRS). To evaluate the association of day 30 vs day 90 mRS, weighted kappa agreement was computed and then adjusted using multivariable ordinal logistic modeling. RESULTS: Overall, mean age was 67.6 +/- 12.4 years; 2,541 (45.2%) were women. Day 30 mRS score correlated strongly with day 90 (r = 0.87, p < 0.001); weighted kappa agreement was 0.86 (95% confidence interval 0.85-0.87, p < 0.001). In multivariable logistic regression analysis, day 30 mRS was the dominant variable associated with day 90 mRS, accounting for 65.6% of the variance. Nine other baseline variables were associated with outcome, but collectively explained only an additional 1.8% of the variance. CONCLUSIONS: After an index ischemic stroke, global disability status at 1 month reliably estimates final 3-month disability outcomes. One-month disability status alone may be dependable and efficient as an outcome measure in stroke quality improvement programs and select clinical trials.
Authors: Myzoon Ali; Philip M W Bath; John Curram; Stephen M Davis; Hans-Christoph Diener; Geoffrey A Donnan; Marc Fisher; Barbara A Gregson; James Grotta; Werner Hacke; Michael G Hennerici; Marc Hommel; Markku Kaste; John R Marler; Ralph L Sacco; Philip Teal; Nils-Gunnar Wahlgren; Steven Warach; Christopher J Weir; Kennedy R Lees Journal: Stroke Date: 2007-04-19 Impact factor: 7.914
Authors: Viren D Patel; Roxanna M Garcia; Dionne E Swor; Eric M Liotta; Matthew B Maas; Andrew Naidech Journal: J Stroke Cerebrovasc Dis Date: 2020-05-15 Impact factor: 2.136
Authors: J Jaime Miranda; Miguel G Moscoso; Lijing L Yan; Francisco Diez-Canseco; Germán Málaga; Hector H Garcia; Bruce Ovbiagele Journal: J Neurol Sci Date: 2017-02-15 Impact factor: 3.181
Authors: Andrew M Naidech; Jennifer L Beaumont; Michael Berman; Eric Liotta; Matthew B Maas; Shyam Prabhakaran; Konrad Kording; Jane Holl; David Cella Journal: Neurocrit Care Date: 2015-08 Impact factor: 3.210
Authors: Adam de Havenon; David L Tirschwell; Laura Heitsch; Steven C Cramer; Robynne Braun; John Cole; Vivek Reddy; Jennifer J Majersik; Arne Lindgren; Bradford B Worrall Journal: Neurol Clin Pract Date: 2021-06
Authors: Andrew M Naidech; Jennifer L Beaumont; Neil F Rosenberg; Matthew B Maas; Adam R Kosteva; Michael L Ault; David Cella; E Wesley Ely Journal: Am J Respir Crit Care Med Date: 2013-12-01 Impact factor: 21.405
Authors: Andrew K ElHabr; Jeffrey M Katz; Jason Wang; Mehrad Bastani; Gabriela Martinez; Michele Gribko; Danny R Hughes; Pina Sanelli Journal: BMJ Neurol Open Date: 2021-06-24